Full Text View
Tabular View
Study Results
Related Studies
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis (ELITE)
This study has been completed.
Study NCT00391976   Information provided by Novartis

First Received on October 19, 2006.   Last Updated on July 29, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Additional conditions recognized in this trial
Fibrosis
Pseudomonas Infections
Respiratory Tract Infections
More general conditions related to this trial
Bacterial Infections
Digestive System Diseases
Genetic Diseases, Inborn
Gram-Negative Bacterial Infections
Infant, Newborn, Diseases
Infection
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Additional drug interventions recognized in this trial
Tobramycin
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services